Companies › InventVacc Biologicals
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Haemophilus influenzae serotype a vaccine candidate Glycoconjugate vaccine against Haemophilus influenzae serotype a | – | Phase 2 | Haemophilus Influenzae | Feb 2027 |
| Haemophilus influenzae type a (Hia) glycoconjugate vaccine Glycoconjugate vaccine against Haemophilus influenzae serotype A | – | Phase 1 | Haemophilus Influenzae Meningitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06465420 | Haemophilus influenzae type a (Hia) glycoconjugate vaccine | Phase 1 | Haemophilus Influenzae Meningitis | Infectious disease | Oct 2024 |
| NCT07743008 | Haemophilus influenzae serotype a vaccine candidate | Phase 2 | Haemophilus Influenzae | Infectious disease | Feb 2027 |
No annotated target.
–
Aimei Vacin BioPharm (Zhejiang) Biothervax Shenzhen Shenxin Biotechnology OsteoRemedies Jiangsu ProteLight Pharmaceutical & Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.